Weakness reported in FDA approval system for new cardiovascular devices HERE.
The drug approval path has always had such weaknesses, as well. Indeed it would be cost-prohibitive to conduct and await truly strong scientific analyses/screens of products in the medical pipeline. The pressure to opt for speed (and profit) in the process will always overwhelm the emphasis on safety. The solution is